ISPCHIGH SIGNALFINANCIAL10-K

ISPC experienced a dramatic revenue contraction alongside a substantial increase in outstanding shares from 2.5 million to 29.7 million, indicating significant dilution and operational challenges.

The combination of severely contracted revenue and massive share dilution suggests the company underwent substantial restructuring or distressed financing. The 12x increase in share count represents extreme dilution for existing shareholders, while the revenue decline indicates core business deterioration that requires immediate attention.

Comparing 2026-04-01 vs 2025-04-14View on EDGAR →
FINANCIAL ANALYSIS

Revenue declined substantially while the company managed to reduce operating losses modestly through what appears to be cost-cutting measures, evidenced by dramatically lower interest expense and capital expenditures. Current assets roughly doubled, providing some liquidity cushion, though this was offset by the massive equity dilution. The overall picture suggests a company in financial distress that has taken significant restructuring actions to preserve cash while fundamentally altering its capital structure.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-98.6%
$32K454

Capex reduced 98.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Accounts Receivable
Balance Sheet
-96.7%
$1.4M$48K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Current Assets
Balance Sheet
+93.8%
$3.6M$7.0M

Current assets grew 93.8% — improving short-term liquidity or inventory/receivables build.

Interest Expense
P&L
-93.3%
$239K$16K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Revenue
P&L
-79.2%
$9.3M$1.9M

Revenue declined 79.2% — significant demand weakness or market share loss warrants investigation.

Operating Cash Flow
Cash Flow
+48.7%
-$8.3M-$4.2M

Operating cash flow surged 48.7% — exceptional cash generation, highest quality earnings signal.

Operating Income
P&L
+29.5%
-$12.7M-$9.0M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Net Income
P&L
+16.1%
-$12.5M-$10.5M

Net income grew 16.1% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-04-01
PRIOR — 2025-04-14
ADDED
As of April 1, 2026, there were 29,662,250 shares of common stock, par value $0.0001 per share, of the registrant issued and outstanding.
Each reference to a fiscal year in this Annual Report refers to the fiscal year ending in the calendar year indicated (for example, fiscal 2025 refers to the fiscal year ended December 31, 2025).
Our Technology Technology Components The legacy iSpecimen Marketplace has been operational for many years as an external-facing platform designed to facilitate search and matching between researchers and suppliers.
While it supported the Company s growth and market presence, its architecture led to increasing operational complexity and fragmentation across commercial, data, and fulfillment processes.
Recently, the Company made a strategic investment in a new technology platform built on its SalesStack solution to modernize the legacy system.
This new system introduces a cloud-native, next-generation architecture, providing a more secure, scalable, and efficient foundation for the Marketplace.
Key improvements include the adoption of Infrastructure-as-Code which enables automated, consistent, and more secure infrastructure deployment.
In addition, the platform establishes unified storage and workflow management, centralizing code and services to reduce silos, improve maintainability, and lower technical debt.
The new architecture also creates a future-ready foundation with streamlined deployment capabilities, automated security controls, and seamless integration across major cloud environments, including AWS, GCP, and Azure.
Building the Marketplace on SalesStack is an important step in unifying the Company s commercial, operational, and data capabilities within a single, integrated system.
REMOVED
Shares of common stock held by executive officer and director and by each stockholder affiliated with a director or an executive officer have been excluded from this calculation because such persons may be deemed to be affiliates.
This determination of affiliate status is not necessarily a conclusive determination for other purposes.
As of April 14, 2025, there were 2,496,858 shares of common stock, par value $0.0001 per share, of the registrant issued and outstanding.
Each reference to a fiscal year in this Annual Report refers to the fiscal year ending in the calendar year indicated (for example, fiscal 2024 refers to the fiscal year ended December 31, 2024).
As of December 31, 2024, we had more than 7,925 external registered users on the iSpecimen Marketplace platform, representing more than 3,006 unique internet domains.
Collectively, these users logged into the iSpecimen Marketplace more than 162,252 times and performed nearly 19,295 specimen searches yielding more than 3,098 quote requests since its launch.
Our Technology Technology Components The iSpecimen Marketplace technology is comprised of four major functional areas: search, workflow, data and administrative, compliance and reporting.
We continue to invest in the evolution of these areas to improve customer and supplier engagement with the platform; provide operational efficiencies for our suppliers, our customers, and our internal operations; and increase the liquidity of products and services obtained through the platform.
Our core business objective is to retain and grow both researcher and supplier usage of our platform to support biospecimen procurement, as well as to position our Company to explore other adjacent business opportunities that can benefit from the use of the iSpecimen Marketplace.
The primary purpose of the iSpecimen Marketplace is to matchmake between those with access to subjects, specimens, and data, and those with a need for them to power their research.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →